Results 11 to 20 of about 4,697,552 (378)
Comorbidity index for predicting mortality at 6 months after reperfusion therapy
Scientific Reports, 2021 The eligibility of reperfusion therapy has been expanded to increase the number of patients. However, it remains unclear the reperfusion therapy will be beneficial in stroke patients with various comorbidities.
Hyo Suk Nam +33 more
doaj +2 more sources
Neuroprotectants in the Era of Reperfusion Therapy [PDF]
Journal of Stroke, 2018 For decades, numerous pharmacological and non-pharmacological strategies have been evaluated without success to limit the consequences of the ischemic cascade, but more rarely the therapies were explored as add on remedies on individuals also receiving reperfusion therapies.
Á. Chamorro
openaire +4 more sources
Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury [PDF]
International Journal of Molecular Sciences, 2021 Ischemic stroke is one of the leading causes of death, and even timely treatment can result in severe disabilities. Reperfusion of the ischemic stroke region and restoration of the blood supply often lead to a series of cellular and biochemical consequences, including generation of reactive oxygen species (ROS), expression of inflammatory cytokines ...
Songhyun Lim +5 more
openaire +3 more sources
Barriers to Participation in Cardiac Rehabilitation Among Patients with Coronary Heart Disease After Reperfusion Therapy: A Scoping Review. [PDF]
Vasc Health Risk Manag, 2023 Patients with coronary heart disease (CHD) experience many barriers to participate in cardiac rehabilitation (CR) programs. Several studies identify barriers that can affect participation in CR among patients with CHD after reperfusion therapy.
Sugiharto F +4 more
europepmc +2 more sources
Prehospital delay and time to reperfusion therapy in ST elevation myocardial infarction
Journal of Emergencies, Trauma and Shock, 2017 Background: Despite efforts aimed at reducing the prehospital delay and treatment delay, a considerable proportion of patients with ST elevation myocardial infarction (STEMI) present late and receive the reperfusion therapy after unacceptably long time ...
Linsha George +4 more
doaj +2 more sources
Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial. [PDF]
Stroke, 2022 Background: Nelonemdaz is a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, as proven in preclinical ischemia-reperfusion studies.
Hong JM +14 more
europepmc +2 more sources
Socioeconomic Inequalities in Reperfusion Therapy for Acute Ischemic Stroke
Stroke, 2022 Background: Reperfusion therapies (thrombolysis and thrombectomy) are of paramount importance for the recovery after ischemic stroke. We aimed to investigate if socioeconomic status (SES) was associated with the chance of receiving reperfusion therapy ...
Sine Mette Øgendahl Buus +5 more
semanticscholar +1 more source
European Journal of Neurology, 2022 Reperfusion therapy is the mainstay of treatment for acute ischaemic stroke (AIS); however, little is known about the use of reperfusion therapy and time delay amongst immigrants.
G. Mkoma +4 more
semanticscholar +1 more source
Stroke, 2021 BACKGROUND AND PURPOSE The mechanisms linking systemic inflammation to poor outcome in ischemic stroke are not fully understood. The authors investigated if peripheral inflammation following reperfusion therapy leads to an increase in cerebral edema (CED)
Daniela Ferro +7 more
semanticscholar +1 more source
Diagnostic and prognostic utility of brain collaterals in acute ischaemic stroke: Current knowledge and insights on treatment decision-making [PDF]
Romanian Journal of Neurology, 2021 Stroke is a leading cause of death and disability worldwide. The advent of acute reperfusion therapy, intravenous thrombolysis and endovascular thrombectomy, has revolutionised the field of stroke medicine, and neurology in general.
Akansha Sinha +5 more
doaj +1 more source